List of Excipients in Branded Drug LOPID

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Parke-Davis Div of Pfizer Inc	LOPID	gemfibrozil	0071-0737	CALCIUM STEARATE
Parke-Davis Div of Pfizer Inc	LOPID	gemfibrozil	0071-0737	CANDELILLA WAX
Parke-Davis Div of Pfizer Inc	LOPID	gemfibrozil	0071-0737	CELLULOSE, MICROCRYSTALLINE

LOPID (Gemfibrozil) Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

LOPID is the branded formulation of gemfibrozil, an oral fibric-acid derivative used with diet to treat severe hypertriglyceridemia and selected dyslipidemias. Its core composition is commercially mature: immediate-release 300 mg capsules and 600 mg tablets have long been available, generic gemfibrozil is established, and the original product patent and regulatory exclusivity have expired. The strongest commercial opportunities are therefore formulation improvement, supply-chain differentiation, excipient substitution, and niche 505(b)(2) products rather than conventional generic entry.

What is LOPID and how is gemfibrozil formulated?

LOPID contains gemfibrozil, a poorly water-soluble, lipophilic active pharmaceutical ingredient administered orally. The historical product has been marketed as an immediate-release capsule and tablet.

Product characteristic	LOPID profile
Active ingredient	Gemfibrozil
Therapeutic class	Fibric-acid derivative
Primary indications	Severe hypertriglyceridemia and selected dyslipidemias
Historical strengths	300 mg capsules; 600 mg tablets
Administration	Usually taken 30 minutes before morning and evening meals
Dosage form	Immediate-release oral solid
Reference sponsor	Parke-Davis, later associated with Pfizer
FDA pathway	Original NDA; generic products approved through ANDA pathway
Current IP position	Core patent and exclusivity barriers have expired
Biosimilar relevance	None; gemfibrozil is a small molecule

The 600 mg tablet is generally the more commercially relevant strength because it supports the labeled twice-daily regimen with two tablets per day. The 300 mg capsule provides dose flexibility but is less attractive for routine adult use because it requires four capsules per day at the standard 1,200 mg daily dose.[1]

What excipients are used in LOPID and generic gemfibrozil products?

The exact inactive-ingredient profile depends on the manufacturer and dosage form. Historical LOPID tablets used conventional excipients associated with immediate-release oral solids, including fillers, disintegrants, binders, lubricants, glidants, coating materials, and colorants. Generic gemfibrozil products may use different excipient systems while maintaining the same active ingredient, strength, dosage form, route, and bioequivalence requirements.

Typical excipient functions include:

Excipient function	Candidate materials	Commercial purpose
Diluent or filler	Microcrystalline cellulose, lactose, starch	Controls tablet weight and compression
Binder	Pregelatinized starch, povidone, hypromellose	Improves granule and tablet cohesion
Disintegrant	Croscarmellose sodium, sodium starch glycolate, crospovidone	Promotes tablet breakup
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces ejection force and tooling adhesion
Glidant	Colloidal silicon dioxide	Improves powder flow
Film coating	Hypromellose, titanium dioxide, polyethylene glycol	Controls appearance, handling, and swallowability
Surfactant or wetting aid	Polysorbate 80, sodium lauryl sulfate	Can improve wetting of hydrophobic gemfibrozil
Capsule shell	Gelatin or hypromellose	Provides encapsulation and product identification

Formulation records should be evaluated product by product. A generic applicant cannot assume that the historic LOPID inactive-ingredient profile is mandatory. The relevant constraints are pharmaceutical equivalence, bioequivalence, quality standards, labeling, and FDA inactive-ingredient requirements.[2]

Why does excipient selection matter for gemfibrozil?

Gemfibrozil presents a formulation challenge because hydrophobic drug particles can wet and dissolve slowly in gastrointestinal fluid. Excipient selection can affect dissolution, content uniformity, tablet robustness, and manufacturing yield.

The main technical risks are:

1. Dissolution variability. Hydrophobic particles may show slower wetting and dissolution when particle size, milling energy, or lubricant concentration changes.

2. Over-lubrication. Excess magnesium stearate can create hydrophobic tablet surfaces and reduce dissolution.

3. Compression sensitivity. A formulation with high crystalline filler content may require tighter control of granulation moisture and compression force.

4. Food-related exposure. The product is labeled for administration before meals. Formulation changes that alter dissolution or gastric emptying behavior may require careful comparative pharmacokinetic assessment.

5. Interaction with excipient grade. Particle-size distribution, surface area, moisture content, and peroxide levels can affect manufacturing performance even when the chemical identity of the excipient is unchanged.

6. Patient acceptability. The 600 mg dose creates a relatively large tablet. Coating, tablet shape, debossing, and swallowability are practical sources of differentiation.

What excipient strategies are available for LOPID reformulation?

Conventional immediate-release optimization

The lowest-risk approach is to retain an immediate-release profile while optimizing the excipient ratio. A formulation developer can evaluate:

• Microcrystalline cellulose and starch blends for tablet strength;
• Crospovidone or croscarmellose sodium for rapid disintegration;
• Lower lubricant concentrations to protect dissolution;
• Colloidal silicon dioxide for flow improvement;
• Film coating to improve swallowability and reduce friability;
• Alternative surfactants where justified by dissolution performance.

This strategy is attractive for generic manufacturers because it can improve manufacturability without changing the clinical use of gemfibrozil. Its patent position is weak unless the formulation produces a defined, non-obvious performance advantage.

Wetting and dissolution enhancement

Gemfibrozil formulations can be screened with surfactants, particle engineering, or solid-dispersion approaches. Candidate technologies include:

• Wet granulation with controlled surfactant distribution;
• Micronized or milled gemfibrozil;
• Spray-dried dispersions;
• Amorphous solid dispersions;
• Lipid-based formulations;
• Co-crystal or salt-screening programs, subject to chemical and regulatory feasibility.

The commercial value depends on whether improved dissolution translates into a meaningful product claim. A faster-dissolving tablet alone may not create a defensible market position if the FDA considers it pharmaceutically equivalent to existing products and no clinical benefit is established.

Excipient substitution for supply resilience

Excipient substitution is a practical opportunity where a manufacturer faces:

• Lactose intolerance or customer preference for lactose-free products;
• Gelatin avoidance;
• Regional restrictions on animal-derived materials;
• Shortages or price volatility affecting a particular excipient;
• Need for a common global formulation;
• Cleaner-label positioning.

Potential substitutions include lactose-free fillers, hypromellose capsules, sodium stearyl fumarate instead of magnesium stearate, and alternative superdisintegrants. Each substitution requires compatibility, process, dissolution, stability, and regulatory assessment.

Fixed-dose or combination products

A combination product involving gemfibrozil would face substantial clinical and regulatory complexity. Gemfibrozil has clinically important interactions with several statins, particularly through transporter and metabolic pathways. The FDA label warns against concomitant use with certain statins and identifies increased myopathy and rhabdomyolysis risk.[1]

That interaction profile limits the commercial attractiveness of a gemfibrozil-statin fixed-dose combination. A combination with another lipid-lowering agent would require a clear therapeutic rationale, controlled clinical evidence, and careful labeling. Excipient innovation alone would not resolve the pharmacologic risk.

What patent protection covers LOPID and gemfibrozil formulations?

The original LOPID patent estate is no longer a meaningful barrier to ordinary generic development. The product has been marketed for decades, and generic gemfibrozil products have received FDA approval.

IP category	Current commercial relevance
Original gemfibrozil compound patents	Expired
Original LOPID formulation patents	Expired or commercially irrelevant
Basic immediate-release tablet claims	Weak for new entrants because of extensive prior art
Excipient substitution claims	Possible, but narrow and vulnerable to design-around
Dissolution-performance claims	Potentially useful if supported by unexpected results
Manufacturing-process claims	Potentially useful for cost, yield, or impurity control
New dosage-form claims	Potentially available under a new patent strategy
Method-of-use claims	Limited by mature indications and existing clinical knowledge

A new formulation patent would need more than a list of conventional excipients. Stronger claims could require a specific concentration range, particle-size distribution, manufacturing sequence, dissolution profile, stability result, or pharmacokinetic outcome. Patent applicants should expect prior-art scrutiny because gemfibrozil immediate-release formulations are technically mature.

When does LOPID lose exclusivity and what is the Orange Book status?

LOPID lost practical market exclusivity long ago. FDA-approved generic gemfibrozil products demonstrate that the original NDA no longer blocks ANDA competition.

The Orange Book remains relevant for identifying reference-listed drug status, dosage forms, therapeutic equivalence codes, and any listed patents or exclusivity information. For a mature product such as LOPID, the primary commercial question is not when generic entry will begin. It is whether a new applicant can achieve acceptable margins in an established, price-sensitive market.[2]

Regulatory issue	Assessment
Current generic availability	Established
Remaining brand exclusivity	None of practical commercial significance
Paragraph IV exposure	Low for the historic product; higher only if a later-listed formulation patent exists
180-day generic exclusivity	Applicant-specific and dependent on current ANDA filings
Regulatory pathway for standard generic	ANDA under section 505(j)
Regulatory pathway for differentiated product	Potentially 505(b)(2), depending on the change
Reference product concern	Demonstrating bioequivalence to the applicable reference-listed drug

Are Paragraph IV challenges or litigation likely for LOPID?

Paragraph IV litigation risk for the legacy LOPID product is limited because the principal product and formulation barriers have expired. A generic applicant could still use Paragraph IV certification if a relevant patent were listed for a reference product, but the commercial incentive would be modest unless the market had an attractive price premium or limited competition.

Litigation risk becomes more relevant in three situations:

1. A sponsor launches a new modified-release, solubilized, or combination product.
2. A later patent claims a specific formulation or manufacturing process.
3. A 505(b)(2) applicant seeks approval for a differentiated indication, dosage form, or dosing regimen.

A new formulation patent could be challenged through Paragraph IV certification, post-grant review, inter partes review, district-court litigation, or design-around development. For a conventional 600 mg immediate-release tablet, extensive prior art would make broad patent claims difficult to sustain.

What commercial opportunities exist for LOPID excipients?

Generic manufacturing and cost reduction

The most immediate opportunity is a low-cost, robust 600 mg tablet. Excipient optimization can reduce:

• Granulation time;
• Compression defects;
• Tablet rejection rates;
• Coating consumption;
• Disintegration variability;
• Dependence on a single excipient supplier.

In a mature generic market, small reductions in manufacturing cost can matter more than premium pricing.

Global supply and regional compliance

A global formulation using widely available excipients can reduce country-specific regulatory variation. Hypromellose capsules, lactose-free formulations, and non-animal-derived excipients may support procurement requirements in selected markets.

The commercial benefit is strongest for contract manufacturers and generic companies selling across several jurisdictions. It is weaker for a single-country product with limited volume.

Patient-centered dosage forms

The 600 mg tablet creates an opportunity for:

• Smaller high-density tablets;
• Improved film coating;
• Tablet scoring where legally and technically appropriate;
• Reduced tablet weight through optimized excipient selection;
• Unit-dose packaging;
• Adherence-oriented blister packaging.

These features may improve usability but generally do not create meaningful patent protection by themselves.

505(b)(2) reformulation

A 505(b)(2) strategy could be considered for a new dosage form, modified-release product, or clinically differentiated formulation. The commercial case would require evidence that the product addresses a material limitation of the existing immediate-release product.

Potential value propositions include fewer daily doses, improved tolerability, reduced food dependence, or a defined exposure advantage. Each would require pharmacokinetic and, in some cases, clinical support. A reformulation without a clear clinical or adherence benefit would face reimbursement and generic-substitution pressure.

How does LOPID compare with competing lipid-lowering drugs?

Gemfibrozil competes with fenofibrate products, statins, omega-3 products, and newer triglyceride-lowering therapies. Fenofibrate has generally been more commercially adaptable because of multiple dosage forms and formulations designed around variable food effects. Statins dominate broad LDL-cholesterol management, while gemfibrozil retains a narrower role in selected triglyceride-focused treatment.

Product class	Excipient opportunity	Competitive issue
Gemfibrozil	Immediate-release optimization and supply-cost reduction	Mature, low-margin generic market
Fenofibrate	Micronization, nanocrystals, food-effect management	Broader formulation innovation
Statins	Combination products and high-volume generics	Stronger market penetration
Prescription omega-3 products	Lipid-based delivery systems	Different dosing and clinical positioning
New triglyceride therapies	Specialty formulations and biologic-like manufacturing	Higher development cost, stronger differentiation

Gemfibrozil's principal disadvantage is not the availability of excipients. It is the drug's interaction profile and mature clinical positioning. The best formulation strategy should therefore focus on reliable delivery, patient adherence, manufacturing efficiency, and market access rather than a broad premium-brand claim.

What generic launch risks exist for gemfibrozil?

Generic launch risks include:

• Price erosion from multiple ANDA holders;
• Difficulty obtaining meaningful market share without supply reliability;
• Bioequivalence failure caused by dissolution variability;
• Manufacturing problems associated with high-dose tablet compression;
• Excipient changes that trigger additional regulatory work;
• Limited reimbursement differentiation;
• Pharmacovigilance concerns related to muscle toxicity and drug interactions;
• Weak patent protection for conventional formulations.

A manufacturer should treat gemfibrozil as a supply-chain and operational opportunity, not as a conventional exclusivity play. A differentiated product needs a measurable clinical, pharmacokinetic, or adherence benefit.

How strong is the LOPID patent estate?

The historic LOPID patent estate is weak as a barrier to entry. The active pharmaceutical ingredient, established dosage forms, and core therapeutic uses are old. A new entrant can potentially obtain protection only around a genuinely differentiated formulation, process, delivery system, or use.

The strongest potential claims would be narrow and evidence-based. They might cover a defined particle-size range combined with an excipient ratio, a manufacturing process that reduces impurities, or a dosage form with a demonstrated pharmacokinetic advantage. Broad claims covering gemfibrozil with standard pharmaceutical excipients would face substantial invalidity and obviousness risk.

Key Takeaways

• LOPID is the legacy brand for gemfibrozil, an established immediate-release oral lipid-lowering drug.
• Generic competition is mature, and original product exclusivity has expired.
• The most practical excipient opportunities involve dissolution control, tablet robustness, lactose-free or animal-free systems, and manufacturing-cost reduction.
• Conventional excipient substitution is unlikely to create strong standalone patent protection.
• A new formulation patent would need defined composition and performance data, not a generic excipient list.
• A 505(b)(2) strategy is possible for a clinically differentiated dosage form but would require a clear commercial advantage.
• Gemfibrozil's interaction profile limits the attractiveness of fixed-dose combinations with statins.
• Commercial success is more likely to come from reliable supply, low cost, regional compliance, and patient-friendly packaging than from premium pricing.

FAQs

Is gemfibrozil still commercially attractive for generic manufacturers?

Yes, but primarily as a low-cost, reliable-supply product. The market is mature, so commercial returns depend on manufacturing efficiency, procurement access, and limited competition in specific channels.

Can a new excipient combination for gemfibrozil receive a patent?

Yes, if the combination is novel, non-obvious, adequately described, and supported by unexpected technical or clinical results. Conventional combinations of fillers, binders, disintegrants, and lubricants are unlikely to support broad claims.

Can gemfibrozil be reformulated as an extended-release product?

A sponsor could pursue an extended-release formulation, but it would need to demonstrate controlled exposure, acceptable safety, and a meaningful advantage over the established immediate-release regimen. The interaction profile would remain a central development issue.

Is LOPID subject to biosimilar competition?

No. Gemfibrozil is a chemically synthesized small molecule. Competition occurs through generic drug pathways, not biosimilar approval pathways.

Which excipient issue is most likely to affect gemfibrozil product quality?

Dissolution control is the leading formulation issue. Wetting, particle size, lubricant concentration, granulation conditions, and disintegrant selection can materially affect release from the immediate-release dosage form.

References

1. U.S. Food and Drug Administration. (2023). LOPID (gemfibrozil) tablets and capsules prescribing information. FDA-approved labeling.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.fda.gov/drugs/drug-approvals-and-databases/inactive-ingredients-database

4. U.S. Food and Drug Administration. (2024). ANDA submissions: Amendments and documentation. FDA guidance and generic-drug resources. https://www.fda.gov/drugs/generic-drugs

5. National Library of Medicine. (2024). DailyMed: Gemfibrozil drug labels. https://dailymed.nlm.nih.gov/dailymed/